Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Good morning. After the murder of UnitedHealthcare chief executive Brian Thompson in Manhattan, demand for elite personal ...

Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ET. Company Participants. Frank Mathias - Chief Executive Officer Sebastien Ribault - Chi ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...

Here is a roundup of stories from The Canadian Press designed to bring you up to speed...Party leaders in Western Canada ...

“We are pleased to have dosed the first patient with a treatment that has such stro We ... Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for ...

We received Fast Track Designation for this program from the U.S. Food and Drug Administration (FDA) based on preclinical data in SSTR2-positive NETs regardless of prior treatment response ... with ...

The firm's latest additions, including two brothers, bolster its employee advisor business in Scottsdale, Arizona.